Afatinib in squamous cell carcinoma of the head and neck.

about

Head and neck cancer: improving outcomes with a multidisciplinary approach.AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma.

P2860

Q41522410-79C82D9A-781D-466E-9D38-7D869EA5690D Q48240243-C0C1592F-B72C-4B79-815D-079476E03C68

P2860

Afatinib in squamous cell carcinoma of the head and neck.

Item

http://www.wikidata.org/entity/Q38829891

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Afatinib in squamous cell carcinoma of the head and neck.

@en

type

Item

label

Afatinib in squamous cell carcinoma of the head and neck.

@en

prefLabel

Afatinib in squamous cell carcinoma of the head and neck.

@en

P1476

Afatinib in squamous cell carcinoma of the head and neck.

@en

P2093

Jan Vermorken

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Epidermal growth factor receptor mutations in lung cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.

P304

1295-1301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14656566.2016.1183647

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pol Specenier

P577

2016-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27160335

http://www.w3.org/2001/XMLSchema#string

Afatinib in squamous cell carcinoma of the head and neck.

about

P2860

P2860

Afatinib in squamous cell carcinoma of the head and neck.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698